ESR1 and breast carcinoma: While some studies have suggested that Bazedoxifene alone or in combination with chemotherapy has anti-proliferative effects on ER+ and TNBC cells via STAT3 [110,111,112], there is limited pre-clinical evidence for its use as a breast cancer therapeutic in the context of excessive STAT3 signaling at the present time.